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Background: Bevacizumab has broad anti-tumour activity, but substantial risk of hypertension. No reliable markers are available
for predicting bevacizumab-induced hypertension.
Methods: A genome-wide association study (GWAS) was performed in the phase III bevacizumab-based adjuvant breast cancer
trial, ECOG-5103, to evaluate for an association between genotypes and hypertension. GWAS was conducted in those who had
experienced systolic blood pressure (SBP)4160mmHg during therapy using binary analysis and a cumulative dose model for the
total exposure of bevacizumab. Common toxicity criteria (CTC) grade 3–5 hypertension was also assessed. Candidate SNP
validation was performed in the randomised phase III trial, ECOG-2100.
Results: When using the phenotype of SBP4160mmHg, the most significant association in SV2C (rs6453204) approached and
met genome-wide significance in the binary model (P¼ 6.0 10 8; OR¼ 3.3) and in the cumulative dose model (P¼ 4.7 10 8;
HR¼ 2.2), respectively. Similar associations with rs6453204 were seen for CTC grade 3–5 hypertension but did not meet genome-
wide significance. Validation study from ECOG-2100 demonstrated a statistically significant association between this SNP and
grade 3/4 hypertension using the binary model (P-value¼ 0.037; OR¼ 2.4).
Conclusions: A genetic variant in SV2C predicted clinically relevant bevacizumab-induced hypertension in two independent,
randomised phase III trials.
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Bevacizumab is a monoclonal antibody that targets vascular
endothelial growth factor (VEGFA). Although this drug has broad
anti-tumour properties, there are no validated biomarkers to
predict which subgroup of patients will respond or experience
toxicity. The inability to enrich for the optimal population has been
a barrier to maximum success. To date, bevacizumab has
demonstrated clinically meaningful activity in colon cancer
(Hurwitz et al, 2004), lung cancer (Sandler et al, 2006), renal-cell
cancer (Yang et al, 2003), cervical cancer (Tewari et al, 2013) and
glioblastoma multiforme (Walter Taal et al, 2013). Bevacizumab also
gained accelerated US-FDA approval for metastatic breast cancer
based, in part, on the results of ECOG-2100 (Miller et al, 2007),
a randomised phase III trial of paclitaxel with or without
bevacizumab. On the basis of less absolute differences in
progression-free survival in later trials (AVADO, RIBBON-I, and
RIBBON-II (Miles et al, 2010; Brufsky et al, 2011; Robert et al,
2011)), no overall survival benefit, and due to the unique and
unpredictable toxicity profile, bevacizumab’s US-FDA approval for
breast cancer was rescinded (FDA NEWS RELEASE, 2011).
Despite this, bevacizumab has remained an approved treatment
for breast cancer in the European Union. The early success of
bevacizumab in the metastatic setting led to the development of
ECOG-5103, which tested a standard backbone of chemotherapy
with concurrent or concurrent plus sequential bevacizumab in the
adjuvant setting with results pending maturation of efficacy data.
Two other phase-III adjuvant breast cancer trials, BETH and
BEATRICE (Cameron et al, 2013; Slamon et al, 2013), have been
negative, highlighting the limitations of bevacizumab for breast
cancer in the absence of a successful efficacy marker.
A major limitation of bevacizumab across all cancer types has
been the inability to predict a priori which patients are most likely
to obtain substantial benefit or toxicity from treatment (Schneider
and Sledge, 2011). Validated biomarkers to predict either the
efficacy or toxicity of bevacizumab are lacking, although germline
DNA variants have been previously nominated (Schneider et al,
2012). Hypertension is the most common, serious bevacizumab-
induced toxicity, which can occasionally be life threatening. Herein
we have identified and validated a genetic biomarker for
bevacizumab-induced hypertension in the adjuvant breast cancer
trial, ECOG-5103 (whose efficacy data were not yet available for
this analysis) and the metastatic breast cancer trial, ECOG-2100.
MATERIALS AND METHODS
Genome-wide association study for SNP discovery in ECOG-5103
ECOG-5103 overview. ECOG-5103 (Figure 1) was a phase-III
adjuvant breast cancer trial that randomised 4994 patients to
doxorubicin and cyclophosphamide for four cycles, followed by 12
weeks (four cycles) of weekly paclitaxel (arm A) or to the same
chemotherapy with either concurrent bevacizumab (arm B) or
concurrent plus sequential bevacizumab every 3 weeks (10 additional
cycles) (arm C). Germline DNA was available from 4033 patients
(Figure 2). For those patients that received bevacizumab (arms B and
C), analyses were performed to identify SNP genotypes that were
associated with hypertension. This correlative study was approved by
the Indiana University Institutional Review Board.
ECOG-5103 genotyping, quality control (QC), race designation,
and imputation. Owing to the availability of germline
DNA, genotyping was performed at two independent time points in
non-overlapping study subsets. DNA from an initial 2209 patients was
genotyped by Illumina Genotyping Services (San Diego, CA, USA)
using the HumanOmni1-Quad (41 million SNPs) array. An additional
1222 patients were also genotyped by Illumina Genotyping Services
using the Human OmniExpress (741000 SNPs) array. Both sample sets
used the Illumina BeadChip microarray platform for genotyping and
the Illumina GenomeStudio software for initial genotyping calls. Of
note, SNPs on the OmniExpress were a subset of those on the
HumanOmni1-Quad. Those SNPs not on the HumanOmni1-Quad
were obtained through imputation in the second sample. Genotypes
from both sample sets were imputed to the level of the 1000 genome
project. Imputation was performed with the 1000 Genomes Phase-I-
integrated variant set as reference using the IMPUTE2 software, and all
SNPs were mapped to the human genome version GRCh37.3. Prior to
imputation, SNPs with missing rate 45%, Hardy–Weinberg Equili-
brium (HWE) P-values o0.0001, or minor allele frequency (MAF)
o3% were excluded. A principal component analysis was performed
using Eigenstrat (Price et al, 2006) and data from 11 HapMap phase-III
populations to identify clusters using the first two eigenvectors
computed using all SNPs (Supplementary Figure S1). Only samples
clustering with the European American reference set were retained.
ECOG-5103 case and control definitions for bevacizumab-
induced hypertension
Cases: Blood pressure values were collected as part of standard
clinical assessment prior to administration of therapy throughout the
conduct of the trial. The goal for phenotype development was to
combine clinically relevant and established parameters with the
highest severity that would still allow reasonable statistical power to
detect an association (Supplementary Information 1). Consistent with
the definition for stage-II hypertension developed by the Joint
National Committee (JNC 7) (http://www.nhlbi.nih.gov/guidelines/
hypertension/express.pdf), first occurrence of a systolic blood pressure
(SBP)4160mmHg was selected to define a case. Of note, a baseline
SBP4160mmHg was also an exclusion criterion for eligibility to
enrolment in the parent trial. In addition, another analysis classified
those individuals with grade 3–5 hypertension as cases, determined by
the common toxicity criteria (CTC) version 3.0 (CTC v. 3.0).
Controls: Controls included all patients in arm B and arm C who
met all the following criteria: (1). SBPo140mmHg at baseline
without use of an anti-hypertensive; (2) maintained a median
SBPo140mmHg throughout therapy; (3) did not meet any of the
definitions for cases as outlined above; and (4) received all prescribed
doses of bevacizumab with follow-up at least 3 months beyond the
last dose. Specifically, patients that had bevacizumab held or modified
for other reasons (i.e., disease progression or other toxicity) were
excluded from control designation. See consort diagram; Figure 2.
Statistical analysis. Two hypotheses were evaluated in the
statistical analyses. First, a standard case-control association
(binary) analysis was performed to identify SNPs associated with
the presence or absence of hypertension. Second, an analysis was
performed to identify SNPs associated with the cumulative
bevacizumab dose before becoming a case (i.e., cumulative dose
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Figure 1. Trial schemas for (A) ECOG-5103 and (B) ECOG-2100.
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model). The cumulative dose model was implemented with a Cox
proportional hazard model, in which the dose was computed as the
full dose or censored. Age (p50 vs450) and obesity (body mass
index (BMI) 430; yes/no) were considered as covariates in both
analyses. The P-value threshold was set at P-value o0.05 for
inclusion of covariates in the regression model.
SNPs available on the HumanOmni1-Quad array were used as
the common basis for all statistical analysis. An additive model of
SNP effect was used when testing all hypotheses. The case-control
analysis was conducted using SNPTEST v2.4 (https://mathgen.
stats.ox.ac.uk/genetics_software/snptest/snptest.html). The cumu-
lative dose model was conducted in R (www.r-project.org) using
the coxph function. For all analyses, the P-value threshold for
genome-wide significance was set at 5 10 8 to correct for
multiple comparisons (Barsh et al, 2012).
Candidate SNP validation in ECOG-2100
ECOG-2100 overview. ECOG-2100 was a phase-III breast cancer
trial that randomised patients with metastatic breast cancer that had
not previously received chemotherapy in the metastatic setting to
either paclitaxel (arm B) or paclitaxel with bevacizumab (arm A);
Figure 1. The results of ECOG-2100 have been previously reported
(Miller et al, 2007). 367 patients had DNA available from formalin-
fixed paraffin-embedded (FFPE) primary tumours.
Case and control designation from ECOG-2100: Only patients
randomised to arm A with DNA available for genotyping were
considered (n¼ 185 subjects). Raw blood pressure values were not
available for ECOG-2100; therefore, grade 3–5 hypertension as
determined by CTC version 2.0 criteria was used (compared with
4033 Samples received from ECOG POO
603 Samples removed due to low DNA concentration
179 Samples removed due to low genotyping call
646 Patients from arm A
1505 Patients removed due to
uncompleted treatment, dosage
adjustment, and/or anti-HT
medication usage
483 Patients for super controls
387 EA samples
722 Patients enrolled
368 Patients from Arm A
185 Patients had DNA available from tumor tissue
150 Controls
124 Caucasian*
120 Caucasian controls
35 Cases
29 Caucasian*
* Ancestry informative markers where not available to assign genetically determined race. Caucasian
designation was based on self-report.
4 Patients removed
due to missing dose
information
354 Patients from Arm B
removed; (no bevacizumab)
83 Samples removed due to duplicate
genotyping data or DNA from male patients
3431 Samples sent for genotyping
3252 Samples successfully genotyped
3169 Samples for analysis
2523 Patients for arm B & C with usable clinical data
437 Patients for cases 1988 Patients for controls
201 54 182
SBP>160 mmHg Grade 3–5
HTN=hypertension; EA=European American
Figure 2. Consort diagram for (A) ECOG-5103 and (B) ECOG-2100.
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version 3.0 for ECOG-5103) as the only phenotype definition. Grade
4 hypertension by CTC version 2.0 criteria was similar to version 3.0
(e.g., hypertensive crisis for both). Grade-3 hypertension for version
2.0 was defined as requiring therapy or more intensive therapy than
previously, whereas for version 3.0 it was defined as requiring 41
drug or more intensive therapy than previously. Controls were those
patients that did not have CTC version 2.0 grade 3–5 hypertension
at any point throughout treatment.
ECOG-2100 genotyping and statistical analysis. Germline DNA
was not available from E2100, and thus DNA was extracted from
20-micron paraffin-embedded tissue sections from the primary
tumour using the DNeasy Tissue kit (Qiagen, Valencia, CA, USA)
(Schneider et al, 2008). The SNP in SVC2, rs6453204, was genotyped
in 185 subjects. Genotyping was performed after a pre-amplification
procedure using a TaqMan SNP Genotyping Assay (C__30765975_
10 (Life Technologies, Carlsbad, CA, USA)), which was performed
on the ABI 7900 Fast Real Time PCR platform (Life Technologies).
Allelic discrimination was determined during a post-amplification
plate read by the TaqMan Genotyper software (Life Technologies).
The quality of the SNP genotyping was assessed by confirming that
the SNP did not violate HWE and had MAF similar to previously
reported frequencies. The same analytic models used in the ECOG-
5103 analyses were employed in the ECOG-2100 statistical analysis.
Only age was considered as a covariate in the regression model as
BMI information was not available. The P-value threshold for the
SNP and covariate selection was 0.05.
RESULTS
Clinical associations with hypertension in ECOG-5103. The
percentage of patients who had a hypertensive event defined as
SBP4160mmHg and CTC grade 3–5 hypertension were 10.4%
and 9.5%, respectively. The median first hypertensive event
occurred at cycle #10 for the SBP4160mmHg phenotype and at
cycle #11 for CTC grade 3–5 hypertension phenotype, respectively.
Race was significantly associated with hypertension. African-
Americans were 1.63-fold more likely to develop hypertension
during treatment with bevacizumab as compared with individuals
of other races (P¼ 0.0039). To obviate bias, the analysis sample
was limited to individuals of European descent. Age 450 years
(P¼ 4.3 10 7) and obesity (P¼ 3.7 10 4) were correlated
with an increased likelihood of hypertension. Both age and obesity
were included as covariates in analyses.
Statistical association results in ECOG-5103. The sample sizes
and number of SNPs available for each phenotype are provided in
Table 1. When using SBP4160mmHg as the hypertension criterion,
the most significant association of a genetic variant with bevacizu-
mab-induced hypertension was rs6453204, a SNP in the SV2C gene
located on chromosome 5 with a MAF of 7%. The association
approached genome-wide significance in the binary model (P¼ 6.0
 10 8; OR¼ 3.3) and met genome-wide significance in the
cumulative dose model (P¼ 4.7 10 8; HR¼ 2.2); Figure 3A and
B and Figure 4. See Supplementary Information 2 for comprehensive
association results. No SNPs provided genome-wide evidence of
association using both binary and cumulative dose model, in which
cases were defined as those meeting grade 3/4 hypertension.
The P-values for association with the SV2C SNP, rs6453204 were
6.4 10 5 (OR¼ 2.0) and 3.0 10 4 (HR¼ 2.2) using the binary
model and the cumulative dose model, respectively.
Validation of SV2C in ECOG-2100. We then performed an
independent validation of the SV2C SNP in the clinical trial ECOG-
2100. As previously reported, 14.8% of patients experienced CTC
grade 3–4 hypertension in E2100 (Miller et al, 2007). The median
first occurrence of CTC grade 3–4 hypertension in the subset of 185
patients who had genotyping data appeared at cycle #1.5 but ranged
from cycle #1–29. We found a statistically significant association of
rs6453204 with bevacizumab-induced grade 3–5 hypertension using
the binary model (P¼ 0.037; OR¼ 2.4). Similar results were
obtained using the cumulative dose model, but did not reach
statistical significance (P¼ 0.091; HR¼ 1.9); Table 2.
DISCUSSION
This study revealed a compelling association between bevacizu-
mab-induced hypertension and an SNP in SV2C (rs6453204) in
two randomised phase III trials. Evidence of association was
initially found in the clinical trial ECOG-5103 and further
validated in ECOG-2100. This represents one of the first
pharmacogenomic studies to uncover a predictive biomarker for
hypertension using a genome-wide approach within a phase-III
breast cancer trial and candidate validation in another phase III
trial. Although ECOG-5103 and ECOG-2100 were trials designed
to test bevacizumab for breast cancer, it is highly likely that the
toxicities and corresponding predictive biomarkers transcend
tumour type or setting, as the tumour has little bearing on drug-
induced toxicity. The association with rs6453204 in ECOG-5103
was found using both a binary and cumulative dose model. The
former simply classified each patient as a case or control, whereas
the later model accounted for the total drug exposure and was a
successful methodology previously employed by Baldwin et al
(2012). Thus, we have observed consistent results using both a
dichotomous and a quantitative phenotype.
Synaptic vesicle protein 2 (SV2) is encoded by a small gene
family with three established isoforms: SV2A, SV2B, and SV2C
(Janz and Sudhof, 1999). The SV2C gene encodes for the SV2C
protein, and rs6453204 is an intronic SNP. Recent studies have
identified SNPs in SV2C, which are associated with a gene-smoking
interaction on risk of Parkinson’s disease (Hill-Burns et al, 2013)
and the response to atypical antipsychotics (Ramsey et al, 2013). In
addition, an SNP close to SV2C has been reported as new candidate
loci for impact on venous thromboembolism and coagulation
pathways (Tang et al, 2013). These studies suggest that SV2C may
have various biological and pharmacological implications. SV2
proteins also appear to be specific to both neurons and endocrine
cells, and function to maintain pools of vesicles for calcium-
induced exocytosis (Janz et al, 1999). Specifically relevant to this
phenotype, SV2C has a role in release of catecholamines from
Table 1. Sample and SNP information for hypertension phenotypes in ECOG-5103
Phenotype definition Cases (n) Controls (n) SNPs with INFOo0.3a SNPs with MAFo0.03 Total SNPs used
Systolic blood pressure 4160mmHg 195 387 76 296 114 761 810 372
Grade 3/4 hypertension 177 387 76 296 114 847 810 286
aThis is reported by IMPUTE2 as a measurement of imputation quality. Lower value indicates higher uncertainty of imputation.
BRITISH JOURNAL OF CANCER SNP in SV2C predicts bevacizumab-induced hypertension
1244 www.bjcancer.com |DOI:10.1038/bjc.2014.430
adrenal chromaffin cells (Xu and Bajjalieh, 2001), which certainly
might represent a potential mechanism for impact on blood
pressure. Production of the sodium-retaining hormone aldosterone
may be modulated through adrenocortical connections with the
adrenal medulla (Gallo-Payet et al, 1987). Additional functional
work is needed to elucidate mechanism, but more importantly, to
shed insight to novel therapeutics.
A strength of this study was the detailed review of the clinical
data in ECOG-5103 and ECOG-2100. All of the patients in the
discovery set from ECOG-5103 were part of the same clinical trial
with rigorous attention to consistent treatment and collection of
clinical data. Similarly, the validation cohort was also part of a
clinical trial, ECOG-2100, that provided similar rigorous patient-
to-patient consistency with regard to treatment protocol and
collection of data. Unlike the evaluation of random patients who
received bevacizumab, the use of patients from a clinical trial
eliminates many innate confounders. Cases and controls were
carefully adjudicated based on stringent phenotype criteria, and the
companion genotyping data underwent substantial QC and
filtering. The control samples were carefully evaluated and patients
having any evidence of prior hypertension or who did not
complete a substantial course of bevacizumab were removed from
the analysis. We believe that this careful phenotypic review
provided the best opportunity for identification of a true genetic
association.
One of the challenges of detecting associations with drug-
induced hypertension is the dynamic and multifactorial nature of
hypertension and the variability in measurement. We chose several
complementary approaches to define the phenotype of drug-
induced hypertension. Each was selected because it provided
additional insight. For the primary analysis, we selected stage II
hypertension determined by the Joint National Committee (JNC-7)
as a value (SBP4160mmHg) that had both clinical relevance and
was sufficiently frequent in this population to allow for statistical
power to detect an association. This was the same definition used
to exclude patients from entry in the parent trial owing to
uncontrolled baseline hypertension. We recognised there were
inherent limitations to the use of a single blood pressure value
obtained in an outpatient clinic. Nonetheless, for a pharmacoge-
nomics study of this size, this represented the most objective,
standardised measure readily available. Further, this represented
the same data that are routinely used in the community setting to
make decisions as to whether to add an anti-hypertensive or to
stop the drug. The other phenotype, CTC grade 3–5 hypertension,
was commonly collected, but was subjective and based on the
threshold for an investigator to either add an anti-hypertensive or
to consider the hypertensive event ‘life threatening’. Specifically,
many investigators were aware of this drug-specific toxicity based
on their prior experience, and may have been tempted to treat with
anti-hypertensive agents early to prevent problems later. Thus,
although the threshold of a SBP 4160mmHg may not represent
the optimal value, we believe an absolute threshold was the proper
approach for this phenotype.
Prior data have suggested that those patients who develop
hypertension may fare better from an efficacy standpoint (Olsen
et al, 2004; Schneider et al, 2008; Jain et al, 2010; Rini et al, 2011),
although there are conflicting reports (Hurwitz et al, 2010). This
type of analysis was complicated by the non-uniformity of the
phenotype (as discussed above) and the heterogeneous benefit for
bevacizumab across tumour types and settings. If indeed, those
who get hypertension are those destined to benefit most,
continuation of therapy despite toxicity is critical. Even if an
association between efficacy and toxicity is not valid, however,
optimal management of these patients remains an important goal.
For these reasons, a biomarker that can predict who might be at
risk for this toxicity might be highly valuable in the clinical setting.
For those deemed to be at increased risk of significant hyper-
tension, close monitoring with early intervention or use of
prophylactic anti-hypertensive therapies could be considered.
Additional information that can be gleaned from a genetic
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biomarker is the potential to understand the underlying biology of
the toxicity. Fundamental biological insights can further lead to
novel therapeutic development for treatment or prevention. If
indeed there is a link between hypertension and effectiveness of the
drug, biomarkers for toxicity may also serve as markers for efficacy.
More broadly, an understanding of bevacizumab-induced hyper-
tension might shed light on the pathophysiology and treatments
for common disorders such as essential hypertension.
Prior studies have evaluated an association between candidate
SNPs and bevacizumab-induced hypertension. We previously
identified an association between SNPs in VEGFA and protection
from grade 3/4 hypertension (Schneider et al, 2008) A similar
finding was demonstrated with sunitinib (Kim et al, 2012). In this
study, we specifically probed the genotyped SNPs in VEGFA
(rs2010963, rs1570360) that had previously been associated with
hypertension induced by an anti-angiogenic agent, and none
demonstrated a statistically significant association in E5103 regardless
of phenotype. Thus, although these prior results were provocative,
they could not be validated in this much larger clinical trial.
A weakness of this study is the limited, phenotypic information
available from ECOG-2100; specifically only CTC version
2.0 grade 3/4 hypertension could be analysed. Although similar, it
should be pointed out that the criterion for hypertension was
slightly different between version 2.0 and version 3.0, the latter of
which was used in ECOG-5103. Therefore, it is likely that the
association with the SNP in SV2C may have been underestimated in
the validation cohort owing to a suboptimal phenotype definition.
In addition, it is possible that the characteristics and the
performance status of patients in the metastatic setting (ECOG-
2100) may not mirror those of the patients in the adjuvant
setting (ECOG-5103), which might subsequently impact the
hypertension phenotype. Unfortunately, germline DNA was not
available in ECOG-2100, and FFPE tumour-derived DNA was used.
Therefore, somatic mutations or loss of heterozygosity could have
reduced the power to replicate the SNP in SV2C association
with drug-induced hypertension. This concern was mitigated as
there was no deviation from HWE, and the MAF was similar to
what was expected in the general population. We also examined data
for SV2C in the Cancer Genome Atlas and found no evidence of
recurrent mutation, loss of heterozygosity, nor recurrent copy-
number aberrations (Cerami et al, 2012; Gao et al, 2013). Another
limitation was the insufficient number of cases and controls to
identify markers for patients of African descent. Data from ECOG-
5103 would support that African-Americans are more likely to
experience this toxicity. Thus, work directed at identifying a marker
for the group most likely to experience this toxicity is of utmost
importance.
In summary, we have identified an SNP in SV2C that
predicts bevacizumab-induced hypertension. Future studies
testing early clinical intervention as well as elucidation of the
functionality of this SNP are warranted and are ongoing. Also,
evaluation of SV2C (as well as other candidates) as a marker for
efficacy will be conducted in the E5103 trial, as efficacy data
become available.
Table 2. Summary of P-values and OR by phenotype and analysis model for rs6453204
Phenotype Model Analysis P-value E5103a P-value E2100b OR/HR E5103 OR/HR E2100
SBP4160
Binary Additive 6.0 10 8 NA 3.3 NA
Cumulative dose Additive 4.7 10 8 NA 2.2 NA
Grade 3/4
Binary Additive 3.0 10 4 0.037 2.2 2.4
Cumulative dose Additive 6.4 10 5 0.091 2.0 1.9
Abbreviations: HR¼ hazard ratio; NA¼ not available; OR¼odds ratio; SBP¼ systolic blood pressure.
aStatistical significance is defined as P-valueo5.0 10 8.
bStatistical significance is defined as P-valueo0.05.
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Figure 4. Association results in the SVC2 region for models of
hypertension defined as systolic blood pressure4160mmHg. Results
for all genotyped and imputed SNPs that passed quality-control
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association, shown as  log10(P-value). The most significantly
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